- In May 2024, Sanofi announced an investment of over USD 1.10 billion in biomanufacturing in France, in addition to the USD 2.74 billion already allocated for major projects, reinforcing the company’s strategic commitment to enhancing health sovereignty. This investment aims to bolster Sanofi's biomanufacturing capabilities within France, positioning the company for future growth in biosurgery and healthcare innovation
- In November 2023, Johnson & Johnson MedTech’s Ethicon received approval for its ETHIZIA Hemostatic Sealing Patch, designed to effectively manage and stop disruptive bleeding during surgical procedures. This addition strengthens Ethicon's extensive biosurgery portfolio, meeting urgent needs in controlling surgical bleeding with enhanced precision and reliability
- In October 2023, Stryker launched a new catalog of advanced wound care products that utilize unique bioengineered materials, aimed at accelerating the healing process and reducing the risk of infection in surgical and traumatic injuries. This launch reflects Stryker’s dedication to providing advanced biosurgical solutions for improving patient recovery outcomes
- In September 2023, Medtronic announced that it had received FDA approval for a new bioactive tissue adhesive for soft tissue repair procedures, featuring enhanced bond strength and elasticity. This product allows surgeons to perform advanced techniques with greater ease, enhancing surgical precision and patient safety in biosurgery
- In August 2023, Ethicon, a Johnson & Johnson company, introduced a new surgical mesh for hernia repairs, advancing bioengineering to improve tissue integration and reduce complications and healing times post-surgery. This innovation further strengthens Ethicon’s ongoing commitment to enhancing surgical outcomes and biosurgical solutions
